论文信息 - NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. - 字舞流文

NISCAHN: A phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group.

C. Borel | V. Costes | D. Cupissol | S. Chabaud | J. Fayette | C. Tourneau | L. Geoffrois | L. Digue | J. Guigay | A. Dillies | S. Zanetta | F. Rolland | C. Even | J. Delaye | A. Guyennon | Laurence Bozec Lemoal | Sophie Couchon-Thaunat | I. Jallut | A. Lardy-Cleaud